Trial Profile

A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cantharidin (Primary)
Indications Warts
Focus Therapeutic Use
Acronyms COVE-1
Sponsors Verrica Pharmaceuticals

Most Recent Events

18 Oct 2019 According to a Verrica Pharmaceuticals media release, data are being presented at the 2019 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV.
18 Oct 2019 According to a Verrica Pharmaceuticals media release, company is planning to meet with the FDA to determine next steps on the development of VP-102 for common warts following positive Phase 2 results.
18 Oct 2019 Results presented in a Verrica Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com